Sanofi CEO cautions arthritis drug a 'long shot' in COVID-19, says study results 'imminent'

Sanofi anticipates study results for an arthritis drug repurposed to treat COVID-19 will be available "imminently," said Paul Hudson, CEO of the French drugmaker, which along with Regeneron is testing the immune-blocking therapy Kevzara in two clinical trials.